88,005 Shares in Entrada Therapeutics, Inc. $TRDA Acquired by GSA Capital Partners LLP

GSA Capital Partners LLP acquired a new position in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 88,005 shares of the company’s stock, valued at approximately $648,000.

A number of other hedge funds have also recently bought and sold shares of the company. Baker BROS. Advisors LP boosted its position in Entrada Therapeutics by 4.3% in the 4th quarter. Baker BROS. Advisors LP now owns 5,072,730 shares of the company’s stock valued at $52,148,000 after buying an additional 206,911 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Entrada Therapeutics by 9.5% during the fourth quarter. Wellington Management Group LLP now owns 1,044,758 shares of the company’s stock worth $10,740,000 after acquiring an additional 90,339 shares during the last quarter. Millennium Management LLC raised its position in shares of Entrada Therapeutics by 391.2% during the third quarter. Millennium Management LLC now owns 836,609 shares of the company’s stock worth $4,852,000 after acquiring an additional 666,287 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Entrada Therapeutics by 7.2% during the second quarter. Geode Capital Management LLC now owns 631,554 shares of the company’s stock valued at $4,245,000 after acquiring an additional 42,479 shares during the period. Finally, State Street Corp lifted its stake in shares of Entrada Therapeutics by 2.0% during the fourth quarter. State Street Corp now owns 508,789 shares of the company’s stock valued at $5,230,000 after acquiring an additional 10,174 shares during the period. 86.39% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently commented on the company. Roth Capital reiterated a “buy” rating and issued a $11.00 price objective on shares of Entrada Therapeutics in a research report on Wednesday, August 12th. HC Wainwright downgraded shares of Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 8th. Guggenheim cut their target price on shares of Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating on the stock in a research report on Monday, June 8th. Finally, Weiss Ratings lowered shares of Entrada Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, August 13th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $17.75.

Entrada Therapeutics Stock Performance

Shares of Entrada Therapeutics stock opened at $7.60 on Friday. The firm has a fifty day moving average of $7.02 and a two-hundred day moving average of $9.46. The stock has a market capitalization of $295.94 million, a price-to-earnings ratio of -1.92 and a beta of -0.26. Entrada Therapeutics, Inc. has a 52 week low of $5.02 and a 52 week high of $16.45.

Entrada Therapeutics (NASDAQ:TRDA) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.04). Entrada Therapeutics had a negative return on equity of 57.61% and a negative net margin of 3,537.73%.The company had revenue of $0.90 million during the quarter, compared to the consensus estimate of $2.32 million. As a group, research analysts forecast that Entrada Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

Insider Activity

In other news, major shareholder Ventures V. L.P. 5Am sold 114,756 shares of the business’s stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $6.93, for a total transaction of $795,259.08. Following the completion of the transaction, the insider directly owned 2,848,310 shares in the company, valued at approximately $19,738,788.30. The trade was a 3.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Kush Parmar sold 114,756 shares of the company’s stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $6.93, for a total value of $795,259.08. Following the completion of the sale, the director directly owned 2,848,310 shares of the company’s stock, valued at approximately $19,738,788.30. This trade represents a 3.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 451,014 shares of company stock worth $3,124,822 in the last three months. Insiders own 9.49% of the company’s stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.